Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • BioD, Derma Sciences deal

    BioD LLC, Memphis, Tenn. Derma Sciences Inc. (NASDAQ:DSCI), Princeton, N.J. Business: Dermatology Derma acquired regenerative medicine company BioD for $13.8 million in cash, $7.5 million in stock, up to $30 million in …

    Published on 8/15/2016
  • Bristol-Myers, Aslan deal

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Aslan Pharmaceuticals Pte. Ltd., Singapore Business: Cancer Aslan said Bristol-Myers reacquired rights to develop and commercialize cancer compound ASLAN002 (BMS-…

    Published on 8/15/2016
  • Cancer Research UK, University of Birmingham deal

    Cancer Research UK, London, U.K. University of Birmingham, Birmingham, U.K. Business: Cancer Cancer Research UKs commercial arm, Cancer Research Technology (CRT), and the University of Birminghams commercial arm, Alta …

    Published on 8/15/2016
  • Genmab, Gilead deal

    Genmab A/S (CSE:GEN), Copenhagen, Denmark Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious Genmab granted Gilead an exclusive license to create and develop bispecific antibodies with Genmabs …

    Published on 8/15/2016
  • Gland Pharma, Shanghai Fosun Pharmaceutical deal

    Gland Pharma Ltd., Hyderabad, India Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196;HKSE:2196), Shanghai, China Business: Generics Fosun will acquire an 86% stake in generics and injectables company Gland …

    Published on 8/15/2016
  • MEI Pharma, Helsinn deal

    MEI Pharma Inc. (NASDAQ:MEIP), San Diego, Calif. Helsinn Healthcare S.A., Lugano, Switzerland Business: Cancer MEI granted Helsinn exclusive, worldwide rights to develop and commercialize pracinostat (formerly SB939). …

    Published on 8/15/2016
  • NIH, Kite Pharma deal

    National Institutes of Health, Bethesda, Md. Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Business: Cancer NIH granted Kite an exclusive, worldwide license to IP covering a human anti-CD19 chimeric antigen …

    Published on 8/15/2016
  • Pfenex, Pfizer deal

    Pfenex Inc. (NYSE-M:PFNX), San Diego, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Ophthalmic, Biosimilars Pfizer terminated a deal with Pfenex, returning to the biotech worldwide rights to PF582, a …

    Published on 8/15/2016
  • PixarBio deal

    PixarBio Corp., Medford, Mass. Business: Neurology PixarBio said it is reverse-merging with an undisclosed public entity and plans to raise $20-$30 million in a PIPE. The company expects to be publicly traded on the …

    Published on 8/15/2016
  • Polyphor, Gilead deal

    Polyphor Ltd., Allschwil, Switzerland Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Pharmaceuticals Gilead and Polyphor partnered to discover and develop macrocycle molecules for targets selected by …

    Published on 8/15/2016
  • Selvita, UCSF deal

    Selvita S.A. (Warsaw:SLV), Krakow, Poland University of California San Francisco, San Francisco, Calif. Business: Neurology Selvitas Selvita Inc. subsidiary and the university partnered to develop small molecules to …

    Published on 8/15/2016
  • Vedanta, NYU Langone Medical Center deal

    Vedanta Biosciences Inc., Boston, Mass. New York University Langone Medical Center, New York, N.Y. Business: Cancer Vedanta and New York University Langone Medical Center partnered to develop microbiome-derived cancer …

    Published on 8/15/2016
  • Versartis, Teijin Pharma deal

    Versartis Inc. (NASDAQ:VSAR), Redwood City, Calif. Teijin Pharma Ltd., Tokyo, Japan Business: Endocrine/Metabolic Versartis granted Teijin exclusive, Japanese rights to develop and commercialize somavaratan, a long-…

    Published on 8/15/2016
  • Advaxis, Amgen deal

    Advaxis Inc. (NASDAQ:ADXS), Princeton, N.J. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Cancer Advaxis granted Amgen exclusive, worldwide rights to develop and commercialize ADXS-NEO. Advaxis will receive…

    Published on 8/8/2016
  • Assurex Health, Myriad Genetics deal

    Assurex Health Inc., Mason, Ohio Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Business: Pharmacogenetics Molecular diagnostics company Myriad will acquire pharmacogenomics testing company Assurex for $225 …

    Published on 8/8/2016
  • Bamboo, Pfizer deal

    Bamboo Therapeutics Inc., Chapel Hill, N.C. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Gene/Cell therapy, Musculoskeletal Pfizer acquired the 78% of Bamboo it did not already own for $150 million up front and up …

    Published on 8/8/2016
  • Cha Bio&Diostech, Sorrento deal

    Cha Bio&Diostech Co. Ltd. (KOSDAQ:085660), Seoul, South Korea Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Business: Infectious, Cancer, Gene/Cell therapy Sorrento and Cha will form a JV to develop and …

    Published on 8/8/2016
  • Editas Medicine, Fondazione, Ospedale San Raffaele deal

    Editas Medicine Inc. (NASDAQ:EDIT), Cambridge, Mass. Fondazione Telethon, Milan, Italy Ospedale San Raffaele, Milan, Italy Business: Gene/Cell therapy Editas partnered with Fondazione Telethon and Ospedale San Raffaele …

    Published on 8/8/2016
  • Emergent BioSolutions, Aptevo deal

    Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. Aptevo Therapeutics Inc. (NASDAQ:APVO), Seattle, Wash. Business: Cancer, Hematology Biodefense company Emergent completed its spin out of newco Aptevo, which will …

    Published on 8/8/2016
  • Eureka Therapeutics, Memorial Sloan Kettering, Juno Therapeutics deal

    Eureka Therapeutics Inc., Emeryville, Calif. Memorial Sloan Kettering Cancer Center, New York, N.Y. Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Business: Cancer Memorial Sloan and Eureka granted Juno exclusive,…

    Published on 8/8/2016
  • FirstString Research, Relief Therapeutics deal

    FirstString Research Inc., Mount Pleasant, S.C. Relief Therapeutics Holding AG (SIX:RLF), Zurich, Switzerland Business: Dermatology Relief will acquire dermatology company FirstString in a stock deal. FirstStrings …

    Published on 8/8/2016
  • GlaxoSmithKline, Verily deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Verily Life Sciences, Mountain View, Calif. Business: Other GlaxoSmithKline and Verily formed newco Galvani Bioelectronics to develop and commercialize bioelectronic …

    Published on 8/8/2016
  • Hadassah Medical Organization, BioLineRx deal

    Hadassah Medical Organization, Jerusalem, Israel BioLineRx Ltd. (Tel Aviv:BLRX;NASDAQ:BLRX), Jerusalem, Israel Business: Hepatic The organizations Hadasit Medical Research Services & Development Ltd. technology transfer…

    Published on 8/8/2016
  • Hutchison China, AstraZeneca deal

    Hutchison China MediTech Ltd. (LSE:HCM;NASDAQ:HCM), Hong Kong, China AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Cancer AstraZeneca and Chi-Med amended their 2011 deal to co-develop savolitinib (AZD6094).…

    Published on 8/8/2016
  • Immune Pharmaceuticals deal

    Immune Pharmaceuticals Inc. (NASDAQ:IMNP;SSE:IMNP), New York, N.Y. Business: Neurology Immune will spin out a new company focused on pain and neurology. The newco will own IP for AmiKet and other pain and neurology …

    Published on 8/8/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993